82625-46-5

Basic information

• Product Name: Benzaldehyde, 4-[3-(1-piperidinyl)propoxy]-
• CAS NO: 82625-46-5
• Molecular Formula: C15H21NO2
• Molecular Weight: 247.337
• Mol File: 82625-46-5.mol
• Article Data: 27

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 4-[3-(1-piperidinyl)propoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-[3-(1-piperidinyl)propoxy]-(82625-46-5)
• EPA Substance Registry System: Benzaldehyde, 4-[3-(1-piperidinyl)propoxy]-(82625-46-5)

Safety Data

• Hazardous Substances Data: 82625-46-5(Hazardous Substances Data)

Upstream product

• 1458-63-5 N-(3-chloropropyl)-piperidine 
• 123-08-0 4-hydroxy-benzaldehyde 
• 110-89-4 piperidine 
• 82625-25-0 4-(3-chloropropoxy)benzaldehyde 
• 104-58-5 3-piperidinopropan-1-ol 
• 202191-53-5 toluene-4-sulfonic acid 3-(4-formyl-phenoxy)-propyl ester 
• 109-70-6 1.3-chlorobromopropane 
• 17954-81-3 4-(3-bromopropoxy)benzaldehyde 
• 93543-57-8 3-piperidin-1-yl-propylamine hydrochloride 
• 5472-49-1 1-(3-chloropropyl)piperidine hydrochloride 

Downstream Products

• 105520-51-2 [2-methyl-4-(2,6,6-trimethyl-cyclohex-1-enyl)-butyl]-[4-(3-piperidino-propoxy)-benzyl]-amine 
• 1028458-62-9 (1-(4-(3-(piperidin-1-yl)propoxy)benzyl)piperidin-4-yl)methanol 
• 1158961-44-4 C₂₀H₃₁BrN₂O 
• 1158961-42-2 C₂₀H₃₀F₂N₂O 
• 1158961-30-8 ST-889 
• 1158961-45-5 C₂₀H₃₁ClN₂O 
• 1158961-32-0 C₁₉H₂₉FN₂O 
• 1158961-34-2 C₁₉H₂₉FN₂O 
• 1609110-32-8 1-(4-(3-(piperidin-1-yl)propoxy)benzyl)-N-(prop-2-ynyl)piperidine-4-carboxamide 

Relevant articles and documents

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Design, synthesis and biological evaluation of 2-styryl-5-hydroxy-4-pyrone derivatives and analogues as multiple functional agents with the potential for the treatment of Alzheimer's disease

A novel series of 2-styryl-5-hydroxy-4-pyrone derivatives and analogues were designed and synthesized as H3 receptor antagonism based multitarget-directed ligands (MTDLs) for AD therapy using pharmacophore-combine strategy. The 2-styryl-5-hydro

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers

A series of quinazoline derivatives with benzylidene hydrazine carboxamide were designed and synthesised as EGFR inhibitors. Most compounds exhibited exceptional anti-proliferative activity against A549, HepG2, MCF-7 and H1975 cells. Furthermore, six compounds demonstrated excellent inhibition activity against EGFRWT with the IC50 value both less than 2 nM. Among the six compounds, 44 exhibited the strongest activity (0.4 nM) and potently inhibited EGFRL858R/T790M (0.1 μM). Excitingly, the most potent compound 14 showed excellent enzyme inhibitory activity with 6.3 nM and 8.4 nM for both EGFRWT and EGFRT790M/L858R. The result of AO single staining and Annexin V/PI staining showed that the compound 14 and 44 could induce remarkable apoptosis of A549 cells. The compound 14 arrested the cell cycle at the S phase and compound 44 arrested the cell cycle at the G0 phase in A549 cells. These preliminary results demonstrate that compound 14 and 44 may be promising lead compound-targeting EGFR.